Prof. PeptideProf. Peptide

November 22, 2026

Australia's TGA Tests Seized KLOW, BPC-157/TB-500 and Retatrutide Vials: No TB-500 Found

Australia’s Therapeutic Goods Administration (TGA) tested Synedica-branded peptide vials seized with NSW Police and found that they did not contain what their labels said: no detectable TB-500 in three products labeled with it, including two KLOW blends, and less retatrutide than labeled, varying between samples, in a fourth. The TGA published the results on November 5, 2026 and told consumers to stop using Synedica products.

What the TGA’s laboratory found

The TGA’s advisory says its laboratory testing “found that tested Synedica peptide products did not contain what their labels claimed.” Its table of results:

  • Synedica BPC 157 & TB 500 10 mg: no TB-500 detected.
  • Synedica KLOW 80 mg: no TB-500 detected.
  • Synedica BARBIE KLOW 100 mg: no TB-500 detected.
  • Synedica Retatrutide 10 mg: “contained less retatrutide than stated on the label, with significant variation between samples.”

“This means consumers cannot rely on the product labels to know what substance they are taking or the amount they are receiving,” the advisory says. The products were identified when the TGA assisted the NSW Police State Crime Command with Strike Force Antree, whose inquiries “remain ongoing.”

What KLOW is labeled to contain

Per the advisory, KLOW is labeled as containing GHK-Cu, BPC-157, TB-500, KPV and vitamin B12, and BARBIE KLOW adds melanotan I to the same list. In both tested Synedica KLOW products, one of the named peptides, TB-500, was not detected. The advisory reports only the TB-500 result for these products; it does not say whether the other labeled ingredients were measured or how much of them was found.

What the advisory does not say

The findings are about the Synedica products the TGA tested, seized in one police operation in New South Wales. The advisory does not say that KLOW, BPC-157 and TB-500 blends or retatrutide sold under other brands lack their labeled ingredients, and nothing here extends it to them. What the results show is that, for these products, the label did not match what the vials held.

Peptide status in Australia

The advisory says “most peptide products, including BPC-157, TB-500 and melanotan I, are prescription-only medicines in Australia,” that Synedica products “have not been assessed by us for quality, safety or efficacy,” and that their place of manufacture has not been approved by the TGA. On retatrutide it says the compound “is still undergoing clinical trials in humans and has not been approved by the TGA or any comparable international regulator.”

The TGA has “expanded its priority focus areas to include unapproved peptide products,” citing increased detection of unlawful importation, supply and advertising. Breaches of the Act can carry civil penalties of up to A$1.82 million per breach for individuals and A$18.2 million for corporations, and criminal penalties of up to 7 years’ imprisonment.

What the TGA tells consumers

The TGA’s own instructions in the advisory, quoted:

  • “If you have purchased a Synedica peptide product, do not use it and speak to a health professional if you have concerns about your health.”
  • Take any remaining product “to your local pharmacy for safe disposal.”
  • Professor Robyn Langham, the TGA’s Chief Medical Adviser: “Not only is there a serious risk of a major allergic response, including anaphylaxis, but, when a product does not contain what the label says, consumers can simply not know what is in the substance they are injecting.”

Other regulators this fall

Health Canada reported bacteria in an injectable peptide seized in Ottawa on November 12, 2026; that advisory is covered in Health Canada Finds Bacteria in a Seized Injectable Peptide in Ottawa. In the United States, the legal side of the retatrutide market is in Lilly’s lawsuits against retatrutide sellers, and reported harms from unapproved retatrutide in the JAMA Network Open and BMJ case reports.

Sources

This article is for informational and educational purposes only and does not constitute medical advice. It reports a government advisory about specific products; it makes no safety, efficacy or quality claim about any other product or vendor.

Checked and updated